Horizon Patient Services can partner with you and your patients throughout the treatment journey

See how our team can help support you and your patients every step of the way

Reimbursement Access Specialist (RAS)
Your resource for navigating access and reimbursement

Patient Access Manager (PAM)
Dedicated one-on-one support for your patient

Helpful resources
Available in the Treatment Initiation Kit or at TEPEZZAhcp.com

---

**Insurance investigation**

1. Email or fax the Patient Enrollment Form to initiate Horizon Patient Services
   - Give your patient a Getting Started Brochure
   - Within 1 business day, your patient will receive a welcome phone call from their dedicated PAM
   - In 2 business days, you will receive the Summary of Insurance Benefits
2. Review any insurance restrictions on site of care options with your RAS
   - Reference the Site of Care Guide
3. Review insurance authorization form and/or documentation requirements with your RAS

---

**Insurance approval**

1. Submit the required insurance documentation
   - Download the letter of medical necessity
   - Horizon Patient Services can follow up with the insurance plan
2. Submit the infusion order
   - Reference the Infusion Order Guide
3. If needed, coordinate lab monitoring with your patient’s care team
   - Download the Care Team Notification

---

**Infusions & ongoing assessment**

1. Perform ongoing assessments, including eye exams and lab work, if needed
   - The PAM can check in with your patient throughout treatment

Download resources at TEPEZZAhcp.com

---

Please see Important Safety Information on reverse and accompanying Full Prescribing Information.
INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.

For additional information on TEPEZZA, please see accompanying Full Prescribing Information.